Advertising disclosure — We may earn a commission if you start care through some of these links, at no extra cost to you. How we're funded. Order reflects our editorial rubric and our commercial relationships; scores are ours alone.
Alternatives · ranked for women
Alternatives to yourEra
yourEra lands at #4 on our women's ranking with a Luna Fit Score of 86/100 — our yourEra write-up for women goes through the six factors behind that number. If it isn't the right fit, here are the strongest alternatives for women's GLP-1 care — scored on the same women's-health rubric of PCOS suitability, clinical oversight, price, access, support and fair cancellation.
Our #1 pick for women
Luna Fit
93/100
Ranked #1 · Grade A
CoreAge Rx
The most reliable on-ramp for women: nationwide access to both molecules at one flat, no-surprise price — including tirzepatide, the option many women with insulin resistance want.
That is 7 points above yourEra on the Luna Fit Score (93 to 86). Price, coverage and every factor are set out side by side in yourEra vs CoreAge Rx for women.
Everything below is scored on the same six women's-health factors as yourEra, in our overall ranking order — the graded index of all our reviews has the rest of the ranking.
Trimi
Ranked #8 · Grade B
Luna Fit
84/100
Among the lowest verified prices we log — compounded semaglutide and tirzepatide on a single membership, shipped nationwide. A budget-first on-ramp for women who want tirzepatide access without paying a premium.
A high-transparency program with unusually clear clinician and supply-chain disclosure — you can see who is prescribing and where the medication comes from, which is rarer than it should be.
A tiered compounded program that lays every price on the table — semaglutide, tirzepatide, a microdose lane, and a combo option — with six-month metabolic lab testing and an NAD+ adjacency that speaks to women thinking about metabolism as a whole system.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. Scores are our editorial judgment per the methodology. Not medical advice; see our disclosure.